Ifp Advisors, Inc Collegium Pharmaceutical, Inc Transaction History

Ifp Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$16.14 - $23.55 $96 - $141	-6 Reduced 19.35%	25 $3,000
Q3 2022 Nov 08, 2022	BUY	$15.46 - $20.1 $479 - $623	31 New	31 $3,000
Q4 2018 Jan 23, 2019	SELL	$14.78 - $19.68 $195,835 - $260,760	-13,250 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$14.16 - $24.3 $33,276 - $57,105	2,350 Added 21.56%	13,250 $0
Q2 2018 Aug 07, 2018	BUY	$21.79 - $28.29 $76,265 - $99,015	3,500 Added 47.3%	10,900 $0
Q1 2018 Jun 03, 2019	BUY	$18.15 - $29.21 $16,334 - $26,289	900 Added 13.85%	7,400 $137,000
Q1 2018 May 09, 2018	SELL	$18.15 - $29.21 $16,334 - $26,289	-900 Reduced 12.16%	6,500 $0
Q3 2017 Oct 30, 2017	BUY	$9.15 - $11.97 $9,150 - $11,970	1,000 Added 15.63%	7,400 $78,000
Q1 2017 Jun 03, 2019	BUY	N/A	200 Added 3.23%	6,400 $64,000
Q4 2016 Jun 03, 2019	BUY	N/A	600 Added 10.71%	6,200 $97,000
Q2 2016 Jun 03, 2019	BUY	N/A	5,600	5,600 $66,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.